Eyebiotech Ltd.
Clinical trials sponsored by Eyebiotech Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New eye drug EYE103 takes on lucentis in major trial for Diabetes-Related vision loss Results expected Sep 2026 (estimated)
- New eye drug EYE103 takes on standard treatment for Diabetes-Related vision loss Results expected Mar 2027 (estimated)
-
New eye drug EYE103 takes on standard treatment for Diabetes-Related vision loss
Disease control OngoingThis study tests a new drug called EYE103 (Restoret) against an existing treatment, ranibizumab (Lucentis), for people with diabetic macular edema, a common cause of vision loss in diabetes. About 1,054 participants receive injections into the eye every 4 weeks for a year, then l…
Phase 2/3 • Sponsor: EyeBiotech Ltd. • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New eye drug EYE103 takes on lucentis in major trial for Diabetes-Related vision loss
Disease control OngoingThis study tests a new drug called EYE103 (Restoret) against an existing treatment, ranibizumab (Lucentis), for people with diabetic macular edema, a condition that causes vision loss in diabetes. About 984 participants will receive injections into the eye every 4 weeks for a yea…
Phase 2/3 • Sponsor: EyeBiotech Ltd. • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC